The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Targeting Cancer Cells with BET Bromodomain Inhibitors
Open accessAbstract
Cancer cells are often hypersensitive to the targeting of transcriptional regulators, which may reflect the deregulated gene expression programs that underlie malignant transformation. One of the most prominent transcriptional vulnerabilities in human cancer to emerge in recent years is the bromodomain and extraterminal (BET) family of proteins, which are coactivators that link acetylated transcription factors and histones to the activation of RNA polymerase II. Despite unclear mechanisms underlying the gene specificity of BET protein function, small molecules targeting these regulators preferentially suppress the transcription of cancer-promoting genes. As a consequence, BET inhibitors elicit anticancer activity in numerous malignant contexts at doses that can be tolerated by normal tissues, a finding supported by animal studies and by phase I clinical trials in human cancer patients. In this review, we will discuss the remarkable, and often perplexing, therapeutic effects of BET bromodomain inhibition in cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Selective inhibition of BET bromodomains
Filippakopoulos, P., Qi, J., Picaud, S., Shen, Y., Smith, W. B., Fedorov, O., Morse, E. M., Keates, T., Hickman, T. T., Felletar, I., et al. (2010) · Nature · doi:10.1038/nature09504 · Cited by 4,262 · cited 6×
“…cell lines to JQ1 leads to a rapid eviction of BRD4–NUT from chromatin, followed by a rapid suppression of its direct target genes, such as MYC, and the induction of terminal squamous cell differentiation (Filippakopoulos et al. 2010; Yan et al. 2011; Grayson et al. 2014; Alekseyenko et al. 2015).”
BackgroundMethodInfluentialSuper-enhancers in the control of cell identity and disease
Hnisz, D., Abraham, B. J., Lee, T. I., Lau, A., Saint-André, V., Sigova, A. A., Hoke, H. A., & Young, R. A. (2013) · Cell · doi:10.1016/j.cell.2013.09.053 · Cited by 3,662 · cited 2×
“” Indeed, genes with a large number of enhancers tend to encode lineage-specific and growth-regulatory factors (Hnisz et al. 2013; Whyte et al. 2013).”
BackgroundSelective Inhibition of Tumor Oncogenes by Disruption of Super-Enhancers
Lovén, J., Hoke, H. A., Lin, C. Y., Lau, A., Orlando, D. A., Vakoc, C. R., Bradner, J. E., Lee, T. I., & Young, R. A. (2013) · Cell · doi:10.1016/j.cell.2013.03.036 · Cited by 2,961 · cited 10×
“Using genomic approaches applied to several different cell types, it has been observed that genes with “superenhancers” nearby tend to be more suppressed by JQ1 than randomly chosen expressed genes (Chapuy et al. 2013; Lovén et al. 2013; Peeters et al. 2015).”
BackgroundMethodInfluentialSelf-citationCombinatorial patterns of histone acetylations and methylations in the human genome
Wang, Z., Zang, C., Rosenfeld, J. A., Schones, D. E., Barski, A., Cuddapah, S., Cui, K., Roh, T.-Y., Peng, W., Zhang, M. Q., et al. (2008) · Nature Genetics · doi:10.1038/ng.154 · Cited by 2,331
RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia
Zuber, J., Shi, J., Wang, E., Rappaport, A. R., Herrmann, H., Sison, E. A., Magoon, D., Qi, J., Blatt, K., Wunderlich, M., et al. (2011) · Nature · doi:10.1038/nature10334 · Cited by 1,870
Self-citationPhthalimide conjugation as a strategy for in vivo target protein degradation
Winter, G. E., Buckley, D. L., Paulk, J., Roberts, J. M., Souza, A., Dhe-Paganon, S., & Bradner, J. E. (2015) · Science · doi:10.1126/science.aab1433 · Cited by 1,760 · cited 2×
“A more recent innovation in BET inhibitor design has been to conjugate JQ1 with chemical moieties that promote recruitment of E3 ubiquitin ligases, which leads to polyubiquitylation of BET proteins and proteasome-dependent degradation, a strategy known as proteolysis targeting chimera (PROTAC) (Lu et al. 2015; Winter…”
BackgroundStructure and ligand of a histone acetyltransferase bromodomain
Dhalluin, C., Carlson, J. E., Zeng, L., He, C., Aggarwal, A. K., Zhou, M.-M., & Zhou, M.-M. (1999) · Nature · doi:10.1038/20974 · Cited by 1,732 · cited 3×
“…Press; all rights reserved; doi: 10.1101/cshperspect.a026674 Cite this article as Cold Spring Harb Perspect Med 2017;7:a026674 1 w w w .p er sp ec ti ve si n m ed ic in e. o rg which is present on 46 different proteins encoded in the human genome (Dhalluin et al. 1999; Filippakopoulos et al. 2012).”
BackgroundInfluentialSuppression of inflammation by a synthetic histone mimic
Nicodeme, E., Jeffrey, K. L., Schaefer, U., Beinke, S., Dewell, S., Chung, C.-W., Chandwani, R., Marazzi, I., Wilson, P., Coste, H., et al. (2010) · Nature · doi:10.1038/nature09589 · Cited by 1,563 · cited 5×
“Of note, both JQ1 and iBET are pan-BET bromodomain inhibitors, which do not discriminate between the two bromodomains within the same BET protein, nor among the four BET family members (Filippakopoulos et al. 2010; Nicodeme et al. 2010).”
BackgroundMethodInfluentialHijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4
Lu, J., Qian, Y., Altieri, M., Dong, H., Wang, J., Raina, K., Hines, J., Winkler, J. D., Crew, A. P., Coleman, K., et al. (2015) · Chemistry & Biology · doi:10.1016/j.chembiol.2015.05.009 · Cited by 1,140
Selective Small Molecule Induced Degradation of the BET Bromodomain Protein BRD4
Zengerle, M., Chan, K.-H., & Ciulli, A. (2015) · ACS Chemical Biology · doi:10.1021/acschembio.5b00216 · Cited by 1,056 · cited 2×
“A more recent innovation in BET inhibitor design has been to conjugate JQ1 with chemical moieties that promote recruitment of E3 ubiquitin ligases, which leads to polyubiquitylation of BET proteins and proteasome-dependent degradation, a strategy known as proteolysis targeting chimera (PROTAC) (Lu et al. 2015; Winter…”
BackgroundThe Mediator complex: a central integrator of transcription
Allen, B. L., & Taatjes, D. J. (2015) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3951 · Cited by 922
Getting up to speed with transcription elongation by RNA polymerase II
Jonkers, I., & Lis, J. T. (2015) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3953 · Cited by 876
Chapuy, B., McKeown, M. R., Lin, C. Y., Monti, S., Roemer, M. G. M., Qi, J., Rahl, P. B., Sun, H. H., Yeda, K. T., Doench, J. G., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.11.003 · Cited by 735 · cited 8×
“Using genomic approaches applied to several different cell types, it has been observed that genes with “superenhancers” nearby tend to be more suppressed by JQ1 than randomly chosen expressed genes (Chapuy et al. 2013; Lovén et al. 2013; Peeters et al. 2015).”
BackgroundMethodInfluentialResponse and resistance to BET bromodomain inhibitors in triple-negative breast cancer
Shu, S., Lin, C. Y., He, H. H., Witwicki, R. M., Tabassum, D. P., Roberts, J. M., Janiszewska, M., Jin Huh, S., Liang, Y., Ryan, J., et al. (2016) · Nature · doi:10.1038/nature16508 · Cited by 632 · cited 8×
“Several recent studies have shown that acquired resistance to BET inhibition is associated with nongenetic mechanisms, in association with a global alteration of gene expression that compensates for the effects of BET inhibition (Tang et al. 2014; Fong et al. 2015; Rathert et al. 2015; Shu et al. 2016).”
BackgroundInfluentialNF-κB Directs Dynamic Super Enhancer Formation in Inflammation and Atherogenesis
Brown, J. D., Lin, C. Y., Duan, Q., Griffin, G., Federation, A. J., Paranal, R. M., Bair, S., Newton, G., Lichtman, A. H., Kung, A. L., et al. (2014) · Molecular Cell · doi:10.1016/j.molcel.2014.08.024 · Cited by 614
BET inhibitor resistance emerges from leukaemia stem cells
Fong, C. Y., Gilan, O., Lam, E. Y. N., Rubin, A. F., Ftouni, S., Tyler, D., Stanley, K., Sinha, D., Yeh, P., Morison, J., et al. (2015) · Nature · doi:10.1038/nature14888 · Cited by 545 · cited 6×
“…resistance to BET inhibition is not associated with BRD2/BRD3/BRD4 mutations, but instead is associated with selection for a rare (presumably preexisting) cell population harboring a pattern of gene expression that bypasses BET inhibition (Fong et al. 2015; Rathert et al. 2015; Conery et al. 2016).”
BackgroundInfluentialRahman, S., Sowa, M. E., Ottinger, M., Smith, J. A., Shi, Y., Harper, J. W., & Howley, P. M. (2011) · Molecular and Cellular Biology · doi:10.1128/mcb.01341-10 · Cited by 532 · cited 1×
“The ET domain interacts with several different cofactors, including the demethylase protein JMJD6, the methyltransferase/adaptor protein NSD3, and the chromatin remodeling ATPases CHD4 and BRG1 (Rahman et al. 2011; Shen et al. 2015).”
BackgroundCooperative binding of two acetylation marks on a histone tail by a single bromodomain
Morinière, J., Rousseaux, S., Steuerwald, U., Soler-López, M., Curtet, S., Vitte, A.-L., Govin, J., Gaucher, J., Sadoul, K., Hart, D. J., et al. (2009) · Nature · doi:10.1038/nature08397 · Cited by 469 · cited 3×
“…the intervening X amino acids having small side chains (e.g., glycine or alanine), whereas the second bromodomain (BD2) is more permissive to binding multiacetylated peptides in diverse sequence contexts (Dey et al. 2003; Moriniere et al. 2009; Gamsjaeger et al. 2011; Filippakopoulos et al. 2012).”
BackgroundLi, Q., Peterson, K. R., Fang, X., & Stamatoyannopoulos, G. (2002) · Blood · doi:10.1182/blood-2002-04-1104 · Cited by 456
BRD4 Connects Enhancer Remodeling to Senescence Immune Surveillance
Tasdemir, N., Banito, A., Roe, J.-S., Alonso-Curbelo, D., Camiolo, M., Tschaharganeh, D. F., Huang, C.-H., Aksoy, O., Bolden, J. E., Chen, C.-C., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0217 · Cited by 415 · cited 1×
“The latter phenotype may reflect the emerging role for BRD4 in tumor suppression, and hence BET inhibition might be expected to worsen certain malignancies (Alsarraj and Hunter 2012; Fernandez et al. 2014; Tasdemir et al. 2016).”
BackgroundSelf-citationBET Bromodomains Mediate Transcriptional Pause Release in Heart Failure
Anand, P., Brown, J. D., Lin, C. Y., Qi, J., Zhang, R., Artero, P. C., Alaiti, M. A., Bullard, J., Alazem, K., Margulies, K. B., et al. (2013) · Cell · doi:10.1016/j.cell.2013.07.013 · Cited by 406 · cited 4×
“Transcriptome-level studies have revealed that BET inhibitors suppress hundreds of genes in each cell type (Anand et al. 2013; Chapuy et al. 2013; Lovén et al. 2013; Asangani et al. 2014).”
BackgroundInfluentialCrowe, B. L., Larue, R. C., Yuan, C., Hess, S., Kvaratskhelia, M., & Foster, M. P. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1516813113 · Cited by 83
Cited by
Targeting transcription factors in cancer — from undruggable to reality
Bushweller, J. H. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0196-7 · Cited by 919
“More recently, in collaborative work with Castilla and coworkers, we have shown that treatment of inv(16)-positive AML cells (an ME-1 leukaemia cell line) with this inhibitor increases RUNX1 occupancy across the genome and decreases MYC expression 10-fold via RUNX1 binding to a specific set of enhancer elements and me…”
BackgroundInfluentialPromoter-proximal pausing of RNA polymerase II: a nexus of gene regulation
Core, L., & Adelman, K. (2019) · Genes & Development · doi:10.1101/gad.325142.119 · Cited by 568
YAP/TAZ Signaling and Resistance to Cancer Therapy
Nguyen, C. D. K., & Yi, C. (2019) · Trends in Cancer · doi:10.1016/j.trecan.2019.02.010 · Cited by 437
The emerging role of epigenetic therapeutics in immuno-oncology
Topper, M. J., Vaz, M., Marrone, K. A., Brahmer, J. R., & Baylin, S. B. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0266-5 · Cited by 433
Bromodomains: a new target class for drug development
Cochran, A. G., Conery, A. R., & Sims, R. J. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0030-7 · Cited by 412
Metadata
- Authors
- Xu, Y., & Vakoc, C. R.
- Venue
- Cold Spring Harbor Perspectives in Medicine
- Publisher
- Cold Spring Harbor Laboratory
- Published
- 2017-02-17
- Volume
- 7
- Issue
- 7
- Pages
- a026674
- ISSN
- 2157-1422 (ISSN-L)
- OpenAlex
- W2588654455
- Cited by
- 180
- References
- 22
- Type
- posted content
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.